Doxil (Caelyx): An Exploratory Study with Pharmacokinetics in Patients with Hormone-Refractory Prostate Cancer
February 2000
in “
Anti-cancer drugs
”
Studysummary In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on journals.lww.com →